Please login to the form below

Not currently logged in
Email:
Password:

Glythera appoints Dr Mike Owen

He joins as a non-executive director

Antibody drug conjugate development company, Glythera has appointed Dr Mike Owen as its non-executive director.

Owen brings over 15 years’ experience in the development and commercialisation of biopharmaceuticals and he was previously senior vice president and global head of research of the Biopharmaceuticals R&D unit at GlaxoSmithKline (GSK).

At GSK, Owen was responsible for initiating and growing the group’s pre-clinical and clinical therapeutic antibody pipeline through in-house development and acquisitions.

Since leaving GSK in 2010, he has taken on a number of executive and non-executive roles, most recently at Kyamb where he served as chief scientific officer from its formation as a spin-out from the Sanger Institute.

He said: “I am pleased to be joining the board of Glythera and look forward to working with the board and management team as the company moves its pipeline products towards the clinic.”

Owen is also currently a director of Avacata plc, Blink Biomedical SAS, GammDelta Therapeutics, Ossianix Inc, ReNeuron plc and Zealand Pharma A/S.

Dr Sam Williams, chairman of Glythera, said: “We are delighted to welcome Mike to the board at this exciting time in the company’s development.”

“His experience in advancing scientific discoveries from the lab to commercialisation will be invaluable in helping us fully exploit our unique ADC platform, both in the development of our proprietary product pipeline and building strategic partnerships with large pharma.”

7th August 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

ACCOMPLISH MEANINGFUL HCP ENGAGEMENT ONLINE
The art of delivering valuable customer journeys aligned to your key messages in 2020...
DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...

Infographics